18-month extension of a phase 2 trial in 77 people with MCI or very mild AD: TEAEs in 75.0% given placebo plus delayed ABvac40 booster vs 81.1% newly given ABvac40; serious TEAEs 5.0% vs 16.2%. No ARIA-E, one ARIA-H; the booster induced robust antibody responses.
RCTn = 77
Pascual-Lucas et al. Long-term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study